PT1429845E - Tratamento ou profilaxia da rejeição de enxertos de células produtoras de insulina - Google Patents
Tratamento ou profilaxia da rejeição de enxertos de células produtoras de insulina Download PDFInfo
- Publication number
- PT1429845E PT1429845E PT02754637T PT02754637T PT1429845E PT 1429845 E PT1429845 E PT 1429845E PT 02754637 T PT02754637 T PT 02754637T PT 02754637 T PT02754637 T PT 02754637T PT 1429845 E PT1429845 E PT 1429845E
- Authority
- PT
- Portugal
- Prior art keywords
- graft rejection
- producing cell
- insulin
- cell graft
- prophylaxis
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 4
- 102000004877 Insulin Human genes 0.000 title abstract 2
- 108090001061 Insulin Proteins 0.000 title abstract 2
- 206010052779 Transplant rejections Diseases 0.000 title abstract 2
- 229940125396 insulin Drugs 0.000 title abstract 2
- 238000011321 prophylaxis Methods 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
- 229940124073 Complement inhibitor Drugs 0.000 abstract 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 abstract 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000004074 complement inhibitor Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 150000002596 lactones Chemical class 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 150000003839 salts Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29706901P | 2001-06-08 | 2001-06-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1429845E true PT1429845E (pt) | 2009-06-15 |
Family
ID=23144725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT02754637T PT1429845E (pt) | 2001-06-08 | 2002-06-07 | Tratamento ou profilaxia da rejeição de enxertos de células produtoras de insulina |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US20030003099A1 (https=) |
| EP (1) | EP1429845B1 (https=) |
| JP (1) | JP4476623B2 (https=) |
| CN (1) | CN1524002A (https=) |
| AT (1) | ATE424893T1 (https=) |
| AU (1) | AU2002320828B2 (https=) |
| BR (1) | BR0209319A (https=) |
| CA (1) | CA2445605A1 (https=) |
| DE (1) | DE60231522D1 (https=) |
| ES (1) | ES2322442T3 (https=) |
| IL (1) | IL158384A0 (https=) |
| NO (1) | NO20035434D0 (https=) |
| NZ (1) | NZ529044A (https=) |
| PL (1) | PL364359A1 (https=) |
| PT (1) | PT1429845E (https=) |
| RU (1) | RU2003136730A (https=) |
| WO (1) | WO2002100148A2 (https=) |
| ZA (1) | ZA200307893B (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4318921B2 (ja) * | 2001-02-22 | 2009-08-26 | ノバルティス アクチエンゲゼルシャフト | 移植片の機能発現遅延の処置のための医薬の製造のためのリンパ球ホーミング促進剤の使用 |
| EP2338511A3 (en) * | 2004-05-14 | 2012-07-25 | Alexion Pharmaceuticals, Inc. | Prolongation of survival of an allograft by inhibiting complement activity |
| US7781617B2 (en) * | 2004-07-16 | 2010-08-24 | Kyorin Pharmaceutical Co., Ltd | Effective use method of medicaments and method of preventing expression of side effect |
| KR20070085465A (ko) * | 2004-11-29 | 2007-08-27 | 노파르티스 아게 | Ｓ１ｐ 수용체 효능제의 투여 용법 |
| CA2595960A1 (en) * | 2005-02-08 | 2006-08-17 | Novartis Ag | Antilymphocyte antibody induction by combination of an s1p receptor agonist/modulator and of immunosuppressive drugs |
| US8778327B2 (en) * | 2005-05-11 | 2014-07-15 | Loma Linda University | Substances, compositions and methods for preventing and treating immune-mediated inflammatory disorders |
| US20090191218A1 (en) | 2005-05-11 | 2009-07-30 | Fengchun Li | DNA Vaccines And Methods For The Prevention Of Transplantation Rejection |
| WO2009114735A1 (en) * | 2008-03-12 | 2009-09-17 | Loma Linda University | Dna vaccines and methods for the prevention of transplantation rejection |
| BRPI0619894B8 (pt) * | 2005-12-15 | 2021-05-25 | Mitsubishi Tanabe Pharma Corp | composto de amina e composição farmacêutica |
| JP5722524B2 (ja) * | 2006-03-02 | 2015-05-20 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 補体活性を抑制することによる同種移植片の生存の延長 |
| EP2489729B1 (en) * | 2006-09-28 | 2015-02-25 | Loma Linda University | Apoptotic cell-mediated transfection of mammalian cells with interfering RNA |
| TW200946105A (en) | 2008-02-07 | 2009-11-16 | Kyorin Seiyaku Kk | Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient |
| PL2278960T5 (pl) | 2008-03-17 | 2020-06-29 | Actelion Pharmaceuticals Ltd. | Schemat dawkowania dla selektywnego agonisty receptora sip1 |
| JP2012508215A (ja) * | 2008-11-11 | 2012-04-05 | ノバルティス アーゲー | 有機化合物 |
| PT2356090T (pt) * | 2008-11-11 | 2017-10-16 | Novartis Ag | Formas cristalinas de fingolimod, hcl |
| JP5654587B2 (ja) * | 2009-06-30 | 2015-01-14 | ライフスキャン・インコーポレイテッドＬｉｆｅｓｃａｎ，Ｉｎｃ． | 基礎インスリン療法を算出する分析物試験方法及び装置 |
| BRPI1015133A2 (pt) * | 2009-06-30 | 2016-04-19 | Lifescan Scotland Ltd | sistemas para o gerenciamento de diabetes e métodos |
| BR112012007134A2 (pt) * | 2009-09-29 | 2016-08-23 | Lifescan Scotland Ltd | dispositivo e método de teste de analito para controle de diabetes |
| US9563743B2 (en) * | 2010-02-25 | 2017-02-07 | Lifescan Scotland Limited | Analyte testing method and system with high and low blood glucose trends notification |
| DK2758074T3 (da) | 2011-09-23 | 2020-07-27 | Univ Loma Linda | Bakteriestammer der udtrykker methylasegener og anvendelser deraf |
| US11680273B2 (en) | 2011-09-23 | 2023-06-20 | Loma Linda University | Treatment of autoimmune diseases |
| CN114306643A (zh) * | 2021-11-30 | 2022-04-12 | 中国科学院昆明动物研究所 | 一种恒河猴免疫抑制模型的构建方法及在car-t细胞植活上的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69321823T2 (de) * | 1992-10-21 | 1999-06-02 | Taito Co., Ltd., Tokio/Tokyo | 2-amino-1, 3- propandiolverbindung und immunosuppressium |
| US5679546A (en) * | 1993-09-24 | 1997-10-21 | Cytomed, Inc. | Chimeric proteins which block complement activation |
| CA2184356A1 (en) * | 1994-03-03 | 1995-09-08 | Russell P. Rother | Terminal complement inhibitor fusion genes and proteins |
| GB9624038D0 (en) * | 1996-11-19 | 1997-01-08 | Sandoz Ltd | Organic compounds |
| JPH1180026A (ja) * | 1997-09-02 | 1999-03-23 | Yoshitomi Pharmaceut Ind Ltd | 新規免疫抑制剤、その使用方法およびその同定方法 |
| JP4318921B2 (ja) * | 2001-02-22 | 2009-08-26 | ノバルティス アクチエンゲゼルシャフト | 移植片の機能発現遅延の処置のための医薬の製造のためのリンパ球ホーミング促進剤の使用 |
-
2002
- 2002-06-07 BR BR0209319-7A patent/BR0209319A/pt not_active IP Right Cessation
- 2002-06-07 EP EP02754637A patent/EP1429845B1/en not_active Expired - Lifetime
- 2002-06-07 JP JP2003502981A patent/JP4476623B2/ja not_active Expired - Fee Related
- 2002-06-07 CA CA002445605A patent/CA2445605A1/en not_active Abandoned
- 2002-06-07 CN CNA028098498A patent/CN1524002A/zh active Pending
- 2002-06-07 PL PL02364359A patent/PL364359A1/xx not_active Application Discontinuation
- 2002-06-07 AU AU2002320828A patent/AU2002320828B2/en not_active Ceased
- 2002-06-07 WO PCT/EP2002/006278 patent/WO2002100148A2/en not_active Ceased
- 2002-06-07 AT AT02754637T patent/ATE424893T1/de active
- 2002-06-07 NZ NZ529044A patent/NZ529044A/en unknown
- 2002-06-07 IL IL15838402A patent/IL158384A0/xx unknown
- 2002-06-07 RU RU2003136730/15A patent/RU2003136730A/ru not_active Application Discontinuation
- 2002-06-07 US US10/164,755 patent/US20030003099A1/en not_active Abandoned
- 2002-06-07 DE DE60231522T patent/DE60231522D1/de not_active Expired - Lifetime
- 2002-06-07 ES ES02754637T patent/ES2322442T3/es not_active Expired - Lifetime
- 2002-06-07 PT PT02754637T patent/PT1429845E/pt unknown
-
2003
- 2003-10-09 ZA ZA200307893A patent/ZA200307893B/en unknown
- 2003-12-05 NO NO20035434A patent/NO20035434D0/no not_active Application Discontinuation
-
2006
- 2006-03-09 US US11/372,383 patent/US20060153842A1/en not_active Abandoned
-
2008
- 2008-04-22 US US12/107,726 patent/US20080199465A1/en not_active Abandoned
-
2011
- 2011-06-06 US US13/154,106 patent/US20110236382A1/en not_active Abandoned
-
2013
- 2013-12-05 US US14/098,179 patent/US20140093502A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PL364359A1 (en) | 2004-12-13 |
| EP1429845A2 (en) | 2004-06-23 |
| WO2002100148A3 (en) | 2004-04-22 |
| DE60231522D1 (de) | 2009-04-23 |
| WO2002100148A2 (en) | 2002-12-19 |
| US20030003099A1 (en) | 2003-01-02 |
| US20080199465A1 (en) | 2008-08-21 |
| CA2445605A1 (en) | 2002-12-19 |
| ES2322442T3 (es) | 2009-06-22 |
| NZ529044A (en) | 2008-03-28 |
| US20060153842A1 (en) | 2006-07-13 |
| EP1429845B1 (en) | 2009-03-11 |
| IL158384A0 (en) | 2004-05-12 |
| RU2003136730A (ru) | 2005-05-20 |
| JP4476623B2 (ja) | 2010-06-09 |
| NO20035434D0 (no) | 2003-12-05 |
| US20110236382A1 (en) | 2011-09-29 |
| ATE424893T1 (de) | 2009-03-15 |
| JP2004534788A (ja) | 2004-11-18 |
| AU2002320828B2 (en) | 2006-02-02 |
| ZA200307893B (en) | 2004-09-06 |
| BR0209319A (pt) | 2004-07-20 |
| US20140093502A1 (en) | 2014-04-03 |
| CN1524002A (zh) | 2004-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1429845E (pt) | Tratamento ou profilaxia da rejeição de enxertos de células produtoras de insulina | |
| DE69713151D1 (de) | Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung | |
| UA49869C2 (uk) | Нафтил-заміщені похідні бензимідазолу, фармацевтична композиція, спосіб лікування (варіанти) та спосіб інгібування людського фактора | |
| TNSN00010A1 (fr) | DIPHENYLUREE A SUBSTITUTION ω CARBOXYARYLE SERVANT D'INHIBUTEURS DE RAF KINASE. | |
| PT1293207E (pt) | Utilização de ritonavir (abt-538) para melhoria da farmacocinética de drogas metabolizadas por citocromo p450 num método de tratamento da sida | |
| KR910000169A (ko) | 포유류에서 이식 거부를 억제시키는 라파마이신의 용도 | |
| YU46200A (sh) | N-(supstituisani peto-članog di-ili triaza dinezasićenog prstena)karbonil/guanidin derivati za tretiranje ishemije | |
| FR2757522B1 (fr) | Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent | |
| JO1613B1 (en) | Derivatives of n - (3-hydroxy-4-piperidnil) dihydrobenzofuran, dihydro-2u-benzopyran or dihydro-benzodoxine) carboxymide | |
| NO954996L (no) | Anvendelse av nona- og dekapeptider for fremstilling av et legemiddel for behandling av AIDS | |
| MY109834A (en) | Benzoxazinones as inhibitors of hiv reverse transcriptase | |
| PL323490A1 (en) | Tetralinic compounds exibiting acitity against multgiple-drug refractoriness | |
| EP1745797A3 (en) | Vascularization inhibitors | |
| AU7239996A (en) | Inhibition of tumor necrosis factor alpha | |
| WO2001078653A3 (en) | Graft rejection inhibition with ccr2 inhibitors | |
| NZ330944A (en) | Peptide derivatives | |
| AU6469401A (en) | Pharmaceutically active compounds and methods of use | |
| MY126450A (en) | Crystalline efavirenz | |
| IT1294931B1 (it) | Derivati della 2-amminotetralina procedimento per la loro preparazione e composizioni farmaceutiche che li contengono, attive nella | |
| IL110011A0 (en) | Pharmaceutical compositions for the treatment of schizophrenia | |
| UA66932C2 (en) | Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine | |
| WO2001056551A3 (en) | Method and formulation for treatment of vasoconstriction | |
| AP9801307A0 (en) | Use of 3-amino-4-hydroxbenzoic acid for treatment of retroviral infections. | |
| HRP20040165B1 (hr) | Upotreba citaloprama u liječenju povišenog krvnogtlaka | |
| AU5625194A (en) | Rectal flunisolide compositions for treating inflammatory intestinal disorders |